Bridgebio Pharma says it will seek U.S. approval of BBP-418 for LGMD2i after Phase 3 trial data showed a range of benefits for patients.

Shares of BridgeBio Pharma rose more than 15% to $62.52 in early trading, after the company reported positive top-line ...

All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile ...

(RTTNews) - BridgeBio Pharma, Inc. (BBIO) announced on Tuesday that the FDA has granted Rare Pediatric Disease Designation for BBP-418 for the treatment of Limb-girdle Muscular Dystrophy Type 2I/R9 ...

Impressive data from an interim readout of Bridgebio Pharma Inc.’s BBP-418 in limb-girdle muscular dystrophy type 2I/R9 has the company prepping to meet with the U.S. FDA to discuss plans for the ...

ML Bio Solutions’ sponsored lead-in study is enrolling patients with LGMD2i across twelve sites in the U.S. and internationally, in collaboration with the LGMD-GRASP consortium SAN FRANCISCO, June 11, ...

PALO ALTO, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

To access the live webcast for BridgeBio's calls, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com . A replay of ...

BridgeBio (BBIO) held an investor event last week focused on BBP-418, the company’s candidate for the treatment of Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a rare muscular disease with ...

- Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio believes there is an opportunity to pursue Accelerated Approval in the ...

novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samples Increase in the ratio of glycosylated αDG to total αDG ...

ML Bio Solutions has initiated a Phase 1 clinical trial of BBP-418 in healthy volunteers ML Bio Solutions’ sponsored lead-in study is enrolling patients with LGMD2i across twelve sites in the U.S. and ...